With the recent boom in artificial intelligence (AI), industry is finding ways to best utilize it in advancing the development of potential therapies.
Najat Khan, PhD, chief data science officer and global head, strategy, portfolio & operations, R&D, The Janssen Pharmaceutical Companies of Johnson & Johnson shares her career path and how she became interested in clinical data. She also discusses some current trends in artificial intelligence/machine learning such as utilizing them in drug discovery and making clinical trials more inclusive.
Najat Khan, PhD, is the chief data science officer and global head of strategy, portfolio & operations for R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson. In this combination of leadership roles—unique in the healthcare industry—Najat is responsible for overseeing the Janssen R&D strategy, pipeline and portfolio optimization and investment, and for fully integrating data science and digital health end-to-end across the pharmaceutical pipeline to drive transformational innovation for patients.
The editors of Applied Clinical Trials bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.